<DOC>
	<DOCNO>NCT00025545</DOCNO>
	<brief_summary>RATIONALE : Transplanted peripheral stem cell sometimes reject body 's tissue . Treating donor peripheral stem cell filgrastim may increase number donor white blood cell . This may help decrease rejection transplant cell patient receive treatment acute leukemia . PURPOSE : Phase II trial study effectiveness filgrastim-treated donor peripheral stem cell treat patient acute leukemia undergoing peripheral stem cell transplantation .</brief_summary>
	<brief_title>Filgrastim-Treated Donor Peripheral Stem Cell Transplantation Treating Patients With Acute Leukemia &lt; /p &gt;</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether filgrastim ( G-CSF ) -mobilized allogeneic peripheral blood stem cell transplantation reduce incidence non-leukemic mortality patient acute leukemia . - Determine kinetics durability engraftment treatment regimen patient . - Determine incidence severity acute chronic graft-versus-host disease patient treat regimen . - Determine leukemia-free survival patient treat regimen . OUTLINE : Donors receive filgrastim ( G-CSF ) subcutaneously ( SC ) day -5 -1 . Donors undergo leukapheresis day -1 0 . Patients undergo total body irradiation twice daily day -7 -4 . Patients receive 2 dos intrathecal methotrexate per local guideline day -10 -3 . Patients also receive cyclophosphamide IV day -3 -2 . Patients receive infusion allogeneic peripheral blood stem cell day 0 . PROJECTED ACCRUAL : A total 5-60 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : One follow diagnosis : Primary acute leukemia beyond first remission Highrisk acute myelogenous leukemia Acute lymphoblastic leukemia first remission Must HLAmatched donor identical HLAA , B , DRB1 alleles No HLAmatched identical sibling haploidentical relative incompatible 0 1 HLAA , B , DRB1 locus nonshared haplotype No leukoencephalopathy PATIENT CHARACTERISTICS : Age : 55 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : SGOT great 2 time normal Hepatitis B surface antigen negative No prior hepatitis C Renal : No impaired renal function Creatinine le 2 time normal Cardiovascular : No symptomatic cardiac disease Pulmonary : No active pulmonary disease DLCO least 60 % predict Other : HIV negative No disease malignancy severely limit life expectancy No severe lifethreatening infection within past 2 week No history septate fungal infection disseminate candidiasis PRIOR CONCURRENT THERAPY : Biologic therapy : No prior bone marrow peripheral blood stem cell transplantation Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy great 3,000 cGy whole brain No prior radiotherapy 1,500 cGy chest abdomen At least 6 month since prior involvedfield radiotherapy chest abdomen Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
</DOC>